Millennium Management LLC Purchases 502,853 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Millennium Management LLC raised its position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 34.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,948,552 shares of the company's stock after acquiring an additional 502,853 shares during the period. Millennium Management LLC owned about 1.31% of Xeris Biopharma worth $6,606,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in XERS. Legato Capital Management LLC acquired a new position in shares of Xeris Biopharma in the 4th quarter worth approximately $482,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Xeris Biopharma by 106.2% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 171,332 shares of the company's stock worth $581,000 after buying an additional 88,224 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Xeris Biopharma by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company's stock worth $26,778,000 after buying an additional 133,738 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Xeris Biopharma by 10.5% in the 4th quarter. Principal Financial Group Inc. now owns 113,217 shares of the company's stock worth $384,000 after buying an additional 10,748 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Xeris Biopharma in the 4th quarter worth approximately $45,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Xeris Biopharma Stock Performance

XERS traded down $0.11 during mid-day trading on Friday, reaching $4.93. The stock had a trading volume of 2,399,990 shares, compared to its average volume of 1,953,480. The stock has a market capitalization of $770.98 million, a P/E ratio of -10.96 and a beta of 1.10. The firm's fifty day simple moving average is $4.65 and its two-hundred day simple moving average is $4.03. Xeris Biopharma Holdings, Inc. has a 52 week low of $2.03 and a 52 week high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to the consensus estimate of $57.61 million. As a group, analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on XERS. HC Wainwright reissued a "buy" rating and issued a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Leerink Partners raised their price target on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, March 7th. Oppenheimer raised their price target on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Craig Hallum raised their price target on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $6.25.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the transaction, the insider now directly owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. The trade was a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 6.47% of the stock is owned by corporate insiders.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.